Terri Jerkins, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1538147319
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $433,487 of the $567,246 with a category attached, or 76.4%. Novo Nordisk accounts for 62.6% of it on its own, with 54 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,550 payments — averaging $365.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$355K
- Corcept Therapeutics$86K
- AstraZeneca$51K
- Bayer$36K
- Johnson & Johnson$22K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- plus $16K from 49 others
Across 814 payments — averaging $751.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$326K
- AbbVie$282K
- Xeris Pharmaceuticals, Inc.$4K
What the payments were for
- Consulting fees$37,8237%
- Speaking & faculty fees$433,48776%
- Travel & lodging$62,19811%
- Food & beverage$33,5376%
- Education$2010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$195,067
- RYBELSUS$115,814
- Korlym$82,342
- FARXIGA$49,571
- Kerendia$34,606
- INVOKANA$21,340
- Tresiba$13,939
- Xultophy 100/3.6$3,097
- CYCLOSET$1,914
- iLet Bionic Pancreas$438
- ISTURISA$226
- EVERSENSE E3 SMART TRANSMITTER KIT$192
- CeQur Simplicity$127
- Veozah$120
- t-slim insulin pump$105
- TZIELD$101
How this compares
$567,246 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 38 | $1,325,776 |
| OzempicSemaglutide | 235 | $390,970 |
| FarxigaDapagliflozin Propanediol | 218 | $253,941 |
| Tresiba Flextouch U-100Insulin Degludec | 180 | $125,219 |
| InvokanaCanagliflozin | 79 | $103,035 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $84,389 |
| JardianceEmpagliflozin | 69 | $78,032 |
| TrulicityDulaglutide | 35 | $68,516 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $43,682 |
| EliquisApixaban | 32 | $32,291 |
| RybelsusSemaglutide | 12 | $31,291 |
| Humalog Kwikpen U-100Insulin Lispro | 69 | $26,427 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $25,715 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 16 | $25,222 |
| Novolog FlexpenInsulin Aspart | 65 | $24,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $85,532 | $1,325,77638 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $355,149 | $458,165331 claims |
| AstraZenecaFarxiga | $51,336 | $253,941218 claims |
| Johnson & JohnsonInvokana | $21,743 | $103,03579 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $993 | $95,91984 claims |
| Boehringer IngelheimJardiance, Tradjenta | $286 | $87,00583 claims |
| PfizerEliquis | $159 | $32,29132 claims |
| AbbVieSynthroid | $906 | $7,395118 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $5,409521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
- Cheryl FasslerNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.